Introduction
============

The concentrations and ratios of fat types that people eat have shifted, with marked increases in saturated and ω6 polyunsaturated fatty acids (PUFAs).[@b1-cia-8-585] In South Korea, similar profound quantitative and qualitative changes in fat intake have occurred in the last four decades, particularly the rising intake of saturated fatty acids and ω6 PUFAs.[@b2-cia-8-585] Dietary PUFAs influence the fatty acid (FA) composition of tissue lipids.[@b3-cia-8-585] However, interindividual variability in serum phospholipid FA, as markers of the FA status of an individual, can be attributed to a combination of dietary factors and genetic variation. The key enzymes in PUFA metabolism are Δ5-desaturase and Δ6-desaturase, which are encoded by the *FADS1* and *FADS2* genes, respectively.[@b4-cia-8-585]--[@b6-cia-8-585] These two genes are located in the desaturase gene cluster on chromosome 11q12--13.1. This cluster also includes *FADS3*, a gene that shares 52% and 62% sequence identity with the *FADS1* and *FADS2* genes, respectively, and encodes a desaturase of unknown activity.[@b4-cia-8-585] In addition, dietary PUFAs have been shown to suppress the activity of stearoyl-coenzyme A (CoA) desaturase (Δ9-desaturase),[@b7-cia-8-585] which is encoded by the stearoyl-CoA desaturase gene family and the rate-limiting enzyme in the cellular synthesis of monounsaturated FA (oleic acid; 18:1 n-9) from saturated FA (stearic acid; 18:0 n-9).[@b8-cia-8-585]

A genome-wide association study for plasma PUFAs showed strong evidence for association with the region of chromosome 11 that encodes *FADS1*, *FADS2,* and *FADS3*.[@b9-cia-8-585] The most significant association was between the single-nucleotide polymorphism (SNP) rs174537 (flap structure-specific endonuclease \[*FEN1*\]) near *FADS1* and arachidonic acid (AA, 20:4ω6). Recently, Mathias et al[@b1-cia-8-585] suggested that variants in the Δ5-desaturase enzymatic step likely regulate the efficiency of conversion of medium-chain PUFAs, such as dietary linoleic acid (LA, 18:ω6), to potentially inflammatory PUFAs, such as AA. In our previous study, we investigated the association of *FADS* polymorphism, including rs174537, with PUFAs in serum phospholipids and coronary artery disease-related biomarkers in South Koreans through a case-control study. We also determined the effect of these SNPs on lipid peroxides. We found that rs174537T was associated with a lower proportion of AA in serum phospholipids and reduced coronary artery disease risk, in association with reduced total and low-density lipoprotein cholesterol (LDL-C) and lipid peroxides.[@b10-cia-8-585] However, there are no reports on the effect of *FADS* polymorphisms on age-associated changes in serum phospholipid PUFA composition, proinflammatory cytokines, or oxidative stress markers. Therefore, we followed 122 nonobese men aged between 35 and 59 years without a history of known diseases at baseline for 3 years to investigate the association of *FADS* polymorphisms, including rs174537, with age-associated changes in serum phospholipid PUFA composition. We also examined the effects of these SNPs on lipid peroxides and oxidative stress markers, including oxidized-LDL (ox-LDL) and urinary 8-epi-prostaglandin F~2α~ (8-epi-PGF~2α~).

Materials and methods
=====================

Study population
----------------

A total of 160 healthy nonobese (18.5 ≤ body mass index \[BMI\] \< 30 kg/m^2^) men aged 35--59 years were recruited at a health-promotion center at the National Health Insurance Corporation Ilsan Hospital in South Korea between August and December 2006. Subjects were sedentary, had no history of known disease, and completed a personal health and medical history questionnaire, which served as a screening tool. Exclusion criteria were type 2 diabetes, cardiovascular disease, psychiatric problems, and use of any medication. Written informed consent was obtained from all participants, and the study protocol was approved by the Institutional Review Board of Yonsei University.

Anthropometric parameters and blood collection
----------------------------------------------

Body weight and height were measured in the morning while participants were unclothed and not wearing shoes. BMI was calculated as body weight in kilograms divided by the square of the height in meters (kg/m^2^). Systolic and diastolic blood pressures (SBP and DBP, respectively) were obtained from the left arm of seated patients with an automatic blood pressure monitor (TM-2654; A&D, Tokyo, Japan) after 20 minutes of rest. After overnight fasting, venous blood samples were collected in ethylenediaminetetraacetic acid-treated or plain tubes, separated into plasma and serum, and then stored at −70°C until analysis.

Genotyping of *FADS* gene polymorphisms
---------------------------------------

Genomic DNA was extracted from 5 mL whole blood using a commercially available DNA isolation kit (Wizard genomic DNA purification kit; Promega, Fitchburg, WI, USA) according to the manufacturer's protocol. Based on previous reports of genetic studies and public databases on the *FADS* gene cluster[@b9-cia-8-585],[@b11-cia-8-585] and the HapMap project (<http://www.hapmap.org>), eight relevant *FADS* SNPs were prescreened and four SNPs (*FEN1* rs174537G \> T, *FADS2* rs174575C \> G, *FADS2* rs2727270C \> T, *FADS3* 1000778C \> T) were selected for further analysis ([Table S1](#SD1){ref-type="supplementary-material"}).

Serum lipid profile and fasting glucose
---------------------------------------

Fasting serum total cholesterol and triglyceride (TG) were measured using a 7150 Autoanalyzer (Hitachi, Tokyo, Japan). After precipitation of serum chylomicrons using dextran sulfate magnesium, HDL-cholesterol concentrations in the supernatants were enzymatically measured. LDL-C was estimated indirectly using the Friedewald formula for subjects with serum TG concentrations \<400 mg/dL (4.52 mol/L). In subjects with serum TG concentrations ≥ 4.52 mol/L (400 mg/mL), LDL-C was directly measured by an enzymatic method on the 7150 Autoanalyzer. Fasting glucose was measured by the glucose oxidase method using a glucose analyzer (Beckman Coulter, Brea, CA, USA).

Plasma ox-LDL and serum high-sensitivity C-reactive protein
-----------------------------------------------------------

Plasma ox-LDL was measured using an enzyme immunoassay (Mercodia, Uppsala, Sweden). The resulting color reaction was read at 450 nm on a Wallac Victor^2^ multilabel counter (PerkinElmer, Waltham, MA, USA). High-sensitivity C-reactive protein (hs-CRP) levels were measured on an Express Plus™ autoanalyzer (Chiron Diagnostics Co., Walpole, MA, USA) using commercially available hs-CRP-Latex (II) X2 kits (Seiken Laboratories Ltd., Tokyo, Japan) that allowed detection of CRP in the range of 0.001--31 mg/dL.

Urinary 8-epi-PGF~2α~ and serum cytokine levels
-----------------------------------------------

Urine was collected in polyethylene tubes containing 1% butylated hydroxytoluene after a 12-hour fast. The tubes were immediately covered with aluminum foil and stored at −70°C until analysis. 8-epi-PGF~2α~ was measured using an enzyme immunoassay (Bioxytech Urinary 8-epi-PGF~2α~ Assay Kit, Oxis International, Portland, OR, USA), and the resulting color reaction was read at 650 nm using a Wallac Victor^2^ multilabel counter. Urinary creatinine was determined by the alkaline picrate (Jaffe) reaction. Urinary 8-epi-PGF~2α~ concentrations were expressed as pg/mg creatinine. Levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α in serum were measured using the Bio-Plex Reagent Kit on a Bio-Plex instrument (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions.

FA composition in serum phospholipids
-------------------------------------

Serum phospholipid FA composition was analyzed by gas chromatography (7890A; Hewlett Packard, Palo Alto, CA, USA) using a modification of a previously described method.[@b12-cia-8-585],[@b13-cia-8-585] Individual FAs were calculated as a relative percentage of the total of 26 FAs (set as 100%) using GC ChemStation software revision B.04.02 (Agilent Technologies, Santa Clara, CA, USA). The activities of Δ5 desaturase and Δ6 desaturase were estimated as the ratios of AA to DGLA and γ-linolenic acid (GLA; 18:3ω6) to LA, respectively.

Assessment of dietary intake and physical activity level
--------------------------------------------------------

The duration of the study was 3 years. At baseline, usual dietary intake for each subject was assessed using a semi-quantitative food-frequency questionnaire and 24-hour recall method.[@b14-cia-8-585] Subjects were encouraged to maintain their body weight within ±2 kg and given general oral and written information about healthy food choices and exercise at baseline and at a subsequent visit (after 3 years). Subjects were instructed by trained dietitians and were also asked to keep food records for 3 days (2 weekdays and 1 weekend day) at each visit. Nutrient intake was determined and calculated as mean values from the 3-day food record using Can-Pro (Korean Nutrition Society, Seoul, South Korea), based on food-composition tables from the National Rural Living Science Institute in South Korea. Total energy expenditure (kcal/d) was calculated from activity patterns, including basal metabolic rate calculated with the Harris--Benedict equation, physical activity for 24 hours, and specific dynamic action of food.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 12.0 for Windows (IBM, Armonk, NY, USA). Hardy--Weinberg equilibrium and linkage disequilibrium tests were examined using Haploview 4.1 (Broad Institute, Cambridge, MA, USA). Frequencies were compared by the Chi-square test. We examined whether each variable was normally distributed before statistical testing, and logarithmic transformation was performed for skewed variables. Paired *t*-tests were used to test between baseline and follow-up values. Differences in clinical variables between the rs174537GG and T-allele carrier groups were tested by independent *t*-test, and a general linear model test was applied to adjust for baseline values. Pearson's correlation coefficients were used to examine the relationships between variables. For descriptive purposes, mean values are presented using untransformed and unadjusted values. Results are expressed as means ± standard error or percentage. A two-tailed value of *P* \< 0.05 was considered statistically significant.

Results
=======

Clinical characteristics, serum phospholipid FA composition, and macronutrient intake at baseline and 3-year follow-up
----------------------------------------------------------------------------------------------------------------------

Among the enrolled men (n = 160), 38 dropped out for personal reasons or poor compliance, leaving 122 men at 3 years. Clinical characteristics, serum phospholipid FA composition, and macronutrient intake at baseline and 3-year follow-up are shown in [Table 1](#t1-cia-8-585){ref-type="table"}. After 3 years, subjects showed an increase in LDL-C (*P* = 0.018), ox-LDL (*P* \< 0.001), serum phospholipid GLA (*P* = 0.024), and AA (*P* = 0.043). HDL-C (*P* = 0.001), IL-6 (*P* = 0.004), and serum phospholipid eicosadienoic acid (20:2ω6) (*P* = 0.016) decreased. There was no significant difference in total energy intake or macronutrient intake between baseline and 3-year follow-up ([Table 1](#t1-cia-8-585){ref-type="table"}).

Genotype distribution of four selected SNPs
-------------------------------------------

Genotype distributions in Hardy--Weinberg equilibrium with 41. 0% GG, 47. 5% GT, and 11. 5% TT at position rs174537; 88.5% CC, 9.8% CG, and 1.6% GG at position rs174575; 48.4% CC, 44.3% CT, and 7.4% TT at position rs2727270; and 49.2% CC, 38.5% CT, and 12.3% TT at position rs1000778. The major alleles were G at position rs174537 (frequency 0.648, *P* = 0.647), C at rs174575 (frequency 0.934, *P* = 0.087), C at rs2727270 (frequency 0.705, *P* = 0.480), and C at position rs1000778 (frequency 0.684, *P* = 0.233). Because the *FADS3* rs1000778C \> T genotype-related PUFA was not significantly different among serum phospholipids, and the *FADS2* rs174575 genotype only showed a trend toward an association with serum phospholipid PUFA (data not shown), we did not perform further analysis on *FADS3* rs1000778C \> T and *FADS2* rs174575C \> G. The genotype and haplotype distributions of *FEN1* rs174537 and *FADS2* rs2727270 were both associated with PUFAs in serum phospholipids. However, because haplotype analysis did not provide information beyond that revealed by each SNP (data not shown), we present only the results of *FEN1* rs174537 and *FADS2* rs2727270.

Serum phospholipid FA composition according to genotypes
--------------------------------------------------------

At baseline, men with the *FEN1* rs174537T allele showed a lower proportion of AA (*P* = 0.007) and lower ratio of AA to LA (*P* = 0.007) in serum phospholipids than those with rs174537GG ([Table 2](#t2-cia-8-585){ref-type="table"}). After 3 years, men with rs174537GG showed a significant increase in AA (*P* = 0.022), ratio of AA to DGLA (*P* = 0.007, [Figure 1](#f1-cia-8-585){ref-type="fig"}), and docosapentaenoic acid (DPA; 22:5ω3) (*P* = 0.044), but a significant decrease in eicosatrienoic acid (20:3ω3) (*P* = 0.037, [Table 2](#t2-cia-8-585){ref-type="table"}). Carriers of the rs174537T allele showed a significant increase in GLA (*P* = 0.031) and a significant decrease in EDA (*P* = 0.030), and the ratio of eicosapentaenoic acid (EPA; 20:5ω3) to α-linolenic acid (ALA; 18:3ω3) (*P* = 0.024). At 3-year follow-up, men with the rs174537T allele showed lower AA (*P* \> 0.001), AA/DGLA (*P* = 0.019, [Figure 1](#f1-cia-8-585){ref-type="fig"}), EPA (*P* = 0.010), DPA (*P* = 0.016), and EPA/ALA (*P* = 0.048) than rs174537GG carriers. Changes in AA (*P* = 0.001), AA/DGLA (*P* = 0.017, [Figure 1](#f1-cia-8-585){ref-type="fig"}), EPA (*P* = 0.004), DPA (*P* = 0.011), and EPA/ALA (*P* = 0.048) were significantly different between rs174537GG men and rs174537T allele carriers after adjusting for baseline values ([Table 2](#t2-cia-8-585){ref-type="table"}). Similar but weaker associations of *FADS2* rs2727270 with PUFAs were also found ([Table S2](#SD2){ref-type="supplementary-material"}).

LDL-cholesterol, hs-CRP, cytokines, and oxidative stress markers according to genotypes
---------------------------------------------------------------------------------------

At baseline, men with the *FEN1* rs174537T allele showed higher serum IL-6 than those with rs174537GG (*P* = 0.038, [Table 3](#t3-cia-8-585){ref-type="table"}). After 3 years, men with rs174537GG showed a significant increase in serum LDL-C (*P* = 0.043) and plasma ox-LDL (*P* \< 0.001). Carriers of the rs174537T allele showed a significant decrease in IL-6 (*P* = 0.001) and a significant increase in ox-LDL (*P* \< 0.001). At 3-year follow-up, men with the rs174537T allele showed lower urinary PGF~2α~ levels (*P* = 0.011) than rs174537GG carriers. Changes in urinary PGF~2α~ levels (*P* \< 0.001) were significantly different between rs174537GG and rs174537T allele carriers after adjusting for baseline values ([Figure 1](#f1-cia-8-585){ref-type="fig"}). Additionally, changes in serum TNF-α (*P* = 0.089) tended to be different ([Table 3](#t3-cia-8-585){ref-type="table"}). Similar associations were found between *FADS2* rs2727270 and LDL-C, hs-CRP, cytokines, and oxidative stress markers ([Table S3](#SD3){ref-type="supplementary-material"}).

Relation of serum phospholipid AA with oxidative stress markers and cytokines
-----------------------------------------------------------------------------

Pearson correlation analysis showed that the changes in the AA proportion in serum phospholipids were positively correlated with changes in urinary 8-epi-PGF~2α~ levels (*r* = 0.249, *P* = 0.007), plasma ox-LDL (*r* = 0.199, *P* = 0.045), and serum IL-6 (*r* = 0.289, *P* = 0.004) in all subjects ([Figure 2](#f2-cia-8-585){ref-type="fig"}). There was a marginal correlation between changes in serum phospholipid AA and changes in serum TNF-α (*r* = 0.191, *P* = 0.058). Additionally, changes in urinary 8-epi-PGF~2α~ levels were positively correlated with changes in serum IL-6 (*r* = 0.242, *P* = 0.015) and TNF-α (*r* = 0.246, *P* = 0.013). Changes in serum IL-6 were positively correlated with changes in serum TNF-α (*r* = 0.464, *P* \< 0.001) and hs-CRP (*r* = 0.507, *P* \< 0.001, [Table 4](#t4-cia-8-585){ref-type="table"}).

Discussion
==========

The major finding of this study is that *FADS* polymorphisms may affect age-associated changes in serum phospholipid long-chain PUFAs, Δ5-desaturase activity, and oxidative stress in middle-aged nonobese men. At 3-year follow-up, there were significant differences between men with *FEN1* rs174537GG and those with the 174537T allele in changes in AA, and Δ5-desaturase activity (determined by the ratio of AA/DGLA), as well as urinary levels of PGF~2α~, one of the radical peroxides of AA, and an indicator of oxidative stress.[@b15-cia-8-585] In particular, the rs174537T allele did not show the age-associated increases in AA and Δ5-desaturase activity seen with the rs174537GG genotype. Therefore, our data show that *FADS* polymorphisms could affect age-associated changes in serum phospholipid long-chain PUFAs, Δ5-desaturase activity, and oxidative stress in middle-aged nonobese men.

Similar to previous studies,[@b1-cia-8-585],[@b16-cia-8-585] the minor variants of rs174537G \> T and rs2727270 were significantly associated with lower concentrations of long-chain PUFAs. However, rs174537G \> T showed stronger association with changes in AA, Δ5-desaturase activity, EPA, DPA, and EPA/ALA than rs2727270. Although numerous SNPs in the *FADS* gene cluster were reported to be significantly associated with FA alterations in tissues, such as serum and red blood cell membranes,[@b1-cia-8-585],[@b9-cia-8-585],[@b11-cia-8-585],[@b17-cia-8-585],[@b18-cia-8-585] a recent genome-wide association study[@b9-cia-8-585] found the most significant association to that of rs174537 with AA. However, rs174537 is located in an intron and in linkage disequilibrium with rs174546 (*r*^2^ = 0.99) and rs3834458 (*r*^2^ = 0.98), which are candidates for a direct influence on gene expression.[@b11-cia-8-585],[@b19-cia-8-585] Therefore, it is possible that this variant is a marker of other functional polymorphisms or is in linkage with currently unidentified causal variants affecting FA concentrations.

AA, a precursor of eicosanoids including prostaglandins and leukotrienes, is liberated from the hydrolysis of the *sn*-2 position of glycerophospholipids (phosphatidylcholine).[@b20-cia-8-585] Radical peroxidation of AA produces a family of prostaglandin F~2~-isomers called F~2~-isoprostanes.[@b21-cia-8-585] One such F~2~-isoprostane, 8-epi-PGF~2α~, is a sensitive and independent risk marker for coronary artery disease.[@b15-cia-8-585],[@b22-cia-8-585],[@b23-cia-8-585] It is probably released into biological fluids through a phospholipase-mediated pathway and consequently excreted in urine. In this study, the changes in the AA proportion in serum phospholipids were positively correlated with changes in urinary 8-epi-PGF~2α~ levels as well as changes in serum IL-6. Interestingly, changes in urinary 8-epi-PGF~2α~ also correlate with changes in IL-6 and TNF-α. This result is consistent with previous findings of a positive association between urinary 8-epi-PGF~2α~ and circulating proinflammatory cytokines.[@b24-cia-8-585]

High concentrations of AA may influence the levels of proinflammatory eicosanoids, which in turn appear to be associated with elevated markers of low-level systemic inflammation.[@b25-cia-8-585]--[@b27-cia-8-585] Thus, low synthesis and availability of AA have been suggested to mitigate the inflammatory response by altering, for example, eicosanoid levels.[@b28-cia-8-585] At 3-year follow-up, men with the rs174537T allele showed lower AA, Δ5-desaturase activity, and urinary PGF~2α~ levels compared to those with rs174537GG. In addition, men with the rs174537T allele also showed significant reduction in IL-6 at 3-year follow-up compared to baseline, and changes in serum TNF-α tended to be different between rs174537GG and rs174537T allele carriers.

Tekola Ayele et al conducted a genome-wide association study of IL-10, IL-1Ra, and IL-6 level in nondiabetic Africans. They reported that IL-6 levels showed genome-wide significant association with one SNP (RP11-314E23.1; chr6:133397598; *P* = 8.63 × 10^−9^), but did not confirm an association of IL-6 with *FADS* genotypes.[@b29-cia-8-585] In addition, Naitza et al investigated a genome-wide association scan on the levels of markers of inflammation including IL-6; however, they did not find an association of IL-6 with *FADS* genotypes either.[@b30-cia-8-585] In our result, at baseline, men with the *FEN1* rs174537T allele showed higher serum IL-6 than those with rs174537GG (*P* = 0.038, [Table 3](#t3-cia-8-585){ref-type="table"}). After adjusting for baseline, changes in IL-6 levels were not significantly different between rs174537GG and rs174537T allele carriers. Thus, we may need to consider further study with an increased number of study subjects in the future to confirm and clarify the result pattern.

Age is known to play an important role in increased LDL oxidation.[@b31-cia-8-585] After 3 years, LDL-C increased in men with rs174537GG, and ox-LDL, one of the products of oxidative stress, increased regardless of genotype. Although the change in ox-LDL in subjects with the rs174537T allele was 33% lower than that of men with GG, it failed to reach statistical significance. However, the present findings of direct correlation between serum phospholipid AA and both plasma ox-LDL and urinary 8-epi-PGF~2α~ could suggest a possible role of AA in lipid peroxidation or oxidative stress during aging. More than 95% of the serum phospholipids are phosphatidylcholine, one of the major phospholipids in membranes. Thus, serum phospholipids mirror membrane composition in the body, as markers of the FA status of an individual.[@b32-cia-8-585]

Several limitations of this study should be mentioned. First, the small sample size was not conducive to identification of weak associations due to low statistical power. Second, PUFA levels were expressed as a percentage of total FAs in serum phospholipids, not as an absolute concentration. Therefore, we were able to detect relative differences in PUFA levels and Δ5-desaturase activity, but unable to decipher the mechanisms, which depend on the absolute values. Third, dietary intake of PUFAs was not investigated in this study, but we confirmed dietary intake of total fat percentage, which did not change for the follow-up period. Finally, we specifically focused on a representative group of South Korean nonobese (18.5 ≤ BMI \< 30 kg/m^2^) men aged 35--59 years. Our subjects were not taking any medications or vitamin/mineral supplementations. Therefore, our data cannot be generalized to other ethnic groups or other populations.

Conclusion
==========

Our data show that *FADS* polymorphisms could affect age-associated changes in serum phospholipid long-chain PUFAs, Δ5-desaturase activity, and oxidative stress in middle-aged nonobese men. In particular, the rs174537T allele did not show age-associated increase in AA and Δ5-desaturase activity seen in the rs174537GG genotype. Because it has been suggested that appropriate dietary intake of FAs can obviously overcome genetic risk factors,[@b33-cia-8-585] these results provide good evidence for tailoring dietary intervention programs to individuals based on their genetic patterns.
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Supplementary tables
====================

###### 

Information for the prescreening of eight single-nucleotide polymorphisms (SNPs) and selection of four SNPs

                        ***FEN1* 10154G \>T**   ***FADS2* rs174575**   ***FADS3* rs1000778**   ***FADS2* rs2727270**   ***FADS2* rs174576**   ***FADS2* rs174570**   ***FADS2* rs174583**   ***FADS3* rs174456**                                                  
  --------------------- ----------------------- ---------------------- ----------------------- ----------------------- ---------------------- ---------------------- ---------------------- ---------------------- ------ ------ ------ ------ ------ ------ ---- ----
  *FEN1* −10154G \> T   --                      --                     --                      --                      --                     --                     --                     --                     --     --     --     --     --     --     --   --
  *FADS2* rs174575      0.96                    0.16                   --                      --                      --                     --                     --                     --                     --     --     --     --     --     --     --   --
  *FADS3* rs1000778     0.21                    0.04                   0.46                    0.04                    --                     --                     --                     --                     --     --     --     --     --     --     --   --
  *FADS2* rs2727270     0.98                    0.71                   1.00                    0.03                    0.13                   0.01                   --                     --                     --     --     --     --     --     --     --   --
  *FADS2* rs174576      1.00                    0.98                   1.00                    0.17                    0.22                   0.04                   1.00                   0.72                   --     --     --     --     --     --     --   --
  *FADS2* rs174570      1.00                    0.98                   1.00                    0.17                    0.21                   0.04                   0.99                   0.71                   1.00   0.99   --     --     --     --     --   --
  *FADS2* rs174583      0.99                    0.95                   0.96                    0.16                    0.22                   0.04                   1.00                   0.71                   0.99   0.98   0.99   0.97   --     --     --   --
  *FADS3* rs174456      0.21                    0.04                   0.46                    0.04                    1.00                   1.00                   0.01                   0.01                   0.22   0.04   0.21   0.04   0.22   0.04   --   --

###### 

Associations of FADS2 rs 2727270 genotypes with polyunsaturated fatty acid (PUFA) composition in serum phospholipids in men at baseline and 3-year follow-up

                                         ***FADS2* rs 2727270C\>T**                                          
  -------------------------------------- ---------------------------- ------- -------------- ------- ------- -------
  **PUFA composition (%) in serum PL**                                                                       
  18:2 (ω6)                                                                                                  
    Baseline                             12.1 ± 0.38                  0.971   12.0 ± 0.42    0.511   0.880   
    Follow-up                            12.1 ± 0.47                          11.6 ± 0.45            0.455   
    Change                               0.02 ± 0.48                          −0.38 ± 0.58           0.594   0.466
  18:3 (ω6)                                                                                                  
    Baseline                             0.18 ± 0.02                  0.215   0.16 ± 0.01    0.051   0.452   
    Follow-up                            0.20 ± 0.01                          0.20 ± 0.01            0.693   
    Change                               0.02 ± 0.02                          0.03 ± 0.02            0.666   0.756
  20:2 (ω6)                                                                                                  
    Baseline                             0.59 ± 0.17                  0.172   0.75 ± 0.18    0.024   0.508   
    Follow-up                            0.36 ± 0.03                          0.51 ± 0.16            0.357   
    Change                               −0.23 ± 0.17                         −0.24 ± 0.11           0.946   0.516
  20:3 (ω6)                                                                                                  
    Baseline                             1.51 ± 0.06                  0.974   1.36 ± 0.06    0.943   0.083   
    Follow-up                            1.52 ± 0.08                          1.36 ± 0.07            0.123   
    Change                               0.00 ± 0.09                          −0.01 ± 0.09           0.941   0.219
  20:4 (ω6)                                                                                                  
    Baseline                             4.73 ± 0.20                  0.027   3.99 ± 0.18    0.559   0.008   
    Follow-up                            5.42 ± 0.27                          4.16 ± 0.23            0.001   
    Change                               0.69 ± 0.30                          0.16 ± 0.28            0.206   0.003
  18:3 (ω3)                                                                                                  
    Baseline                             0.17 ± 0.02                  0.319   0.18 ± 0.03    0.945   0.912   
    Follow-up                            0.21 ± 0.02                          0.18 ± 0.01            0.267   
    Change                               0.04 ± 0.03                          0.00 ± 0.03            0.474   0.268
  20:3 (ω3)                                                                                                  
    Baseline                             0.10 ± 0.02                  0.029   0.08 ± 0.01    0.702   0.276   
    Follow-up                            0.06 ± 0.00                          0.07 ± 0.00            0.123   
    Change                               −0.04 ± 0.02                         −0.01 ± 0.01           0.138   0.128
  20:5 (ω3)                                                                                                  
    Baseline                             1.18 ± 0.07                  0.134   1.06 ± 0.07    0.585   0.240   
    Follow-up                            1.41 ± 0.12                          1.11 ± 0.07            0.033   
    Change                               0.24 ± 0.16                          0.05 ± 0.09            0.293   0.027
  22:5 (ω3)                                                                                                  
    Baseline                             0.54 ± 0.03                  0.088   0.60 ± 0.05    0.250   0.333   
    Follow-up                            0.63 ± 0.04                          0.54 ± 0.04            0.085   
    Change                               0.09 ± 0.05                          −0.06 ± 0.05           0.043   0.058
  22:6 (ω3)                                                                                                  
    Baseline                             2.74 ± 0.18                  0.130   2.69 ± 0.16    0.694   0.819   
    Follow-up                            3.10 ± 0.18                          2.77 ± 0.18            0.205   
    Change                               0.36 ± 0.23                          0.09 ± 0.22            0.399   0.215
  20:4(ω6)/20:3(ω6)                                                                                          
    Baseline                             3.24 ± 0.13                  0.008   3.36 ± 0.39    0.798   0.785   
    Follow-up                            3.84 ± 0.22                          3.25 ± 0.21            0.052   
    Change                               0.60 ± 0.22                          −0.11 ± 0.41           0.134   0.043
  20:4(ω6)/18:2(ω6)                                                                                          
    Baseline                             0.42 ± 0.03                  0.206   0.34 ± 0.02    0.232   0.024   
    Follow-up                            0.50 ± 0.06                          0.42 ± 0.06            0.314   
    Change                               0.08 ± 0.06                          0.07 ± 0.06            0.921   0.377
  20:5(ω3)/18:3(ω3)                                                                                          
    Baseline                             9.36 ± 0.79                  0.148   9.18 ± 0.96    0.060   0.883   
    Follow-up                            7.88 ± 0.64                          6.99 ± 0.58            0.306   
    Change                               −1.49 ± 1.01                         −2.19 ± 1.14           0.646   0.307

**Notes:**

Values derived from paired *t*-test;

values derived from independent *t*-test;

values derived after adjusting for baseline values. Values are means ± standard error.

**Abbreviations:** PUFA, polyunsaturated fatty acid; PL, phospholipids

###### 

Associations of *FADS2* rs2727270 genotypes with LDL cholesterol, hs-CRP, cytokines, and oxidative stress markers in men at baseline and 3-year follow-up

                                                           ***FADS2*rs2727270C\>T**                                               
  -------------------------------------------------------- -------------------------- --------- --------------- --------- ------- -------
  LDL cholesterol (mg/dL)                                                                                                         
    Baseline[^§^](#tfn7-cia-8-585){ref-type="table-fn"}    119.3 ± 4.14               0.035     114.9 ± 4.76    0.184     0.447   
    Follow-up[^§^](#tfn7-cia-8-585){ref-type="table-fn"}   124.5 ± 3.46                         119.2 ± 4.47              0.210   
    Change                                                 5.22 ± 2.98                          4.26 ± 3.51               0.837   0.533
  hs-CRP (mg/dL)                                                                                                                  
    Baseline[^§^](#tfn7-cia-8-585){ref-type="table-fn"}    1.34 ± 0.30                0.972     1.92 ± 0.77     0.534     0.606   
    Follow-up[^§^](#tfn7-cia-8-585){ref-type="table-fn"}   1.45 ± 0.30                          1.65 ± 0.49               0.947   
    Change                                                 0.11 ± 0.15                          −0.27 ± 0.90              0.691   0.477
  Serum IL-6 (pg/mL)                                                                                                              
    Baseline[^§^](#tfn7-cia-8-585){ref-type="table-fn"}    4.27 ± 0.40                0.199     4.87 ± 0.52     0.006     0.407   
    Follow-up[^§^](#tfn7-cia-8-585){ref-type="table-fn"}   3.87 ± 0.39                          3.39 ± 0.34               0.474   
    Change                                                 −0.41 ± 0.46                         −1.48 ± 0.61              0.168   0.268
  Serum TNF-α (pg/mL)                                                                                                             
    Baseline[^§^](#tfn7-cia-8-585){ref-type="table-fn"}    13.4 ± 1.73                0.765     9.53 ± 1.02     0.603     0.067   
    Follow-up[^§^](#tfn7-cia-8-585){ref-type="table-fn"}   11.9 ± 1.68                          8.87 ± 0.57               0.122   
    Change                                                 −1.42 ± 2.24                         −0.66 ± 1.16              0.761   0.303
  8-epi-PGF~2α~ (pg/mg creatinine)                                                                                                
    Baseline[^§^](#tfn7-cia-8-585){ref-type="table-fn"}    1313.0 ± 55.5              0.123     1324.3 ± 75.4   0.809     0.736   
    Follow-up[^§^](#tfn7-cia-8-585){ref-type="table-fn"}   1484.1 ± 76.2                        1243.3 ± 43.9             0.022   
    Change                                                 171.1 ± 93.2                         −80.9 ± 85.1              0.048   0.003
  Oxidized LDL (U/L)                                                                                                              
    Baseline[^§^](#tfn7-cia-8-585){ref-type="table-fn"}    34.0 ± 1.61                \<0.001   35.7 ± 1.96     \<0.001   0.663   
    Follow-up[^§^](#tfn7-cia-8-585){ref-type="table-fn"}   45.9 ± 1.49                          43.4 ± 1.74               0.147   
    Change                                                 11.9 ± 1.65                          7.76 ± 1.87               0.097   0.092

**Notes:**

Tested by logarithmic transformation;

values derived from paired *t*-test;

values derived from independent *t*-test;

values derived after adjusting for baseline values. Values are means ± standard error.

**Abbreviations:** LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; TNF, tumor necrosis factor; IL, interleukin; 8-epi-PGF~2α~, urinary 8-epi-prostaglandin F~2α~.

![Serum phospholipid AA (20:4 ω6), the ratio of 20:4 ω6/20:3 ω6, and urinary levels of 8-epi-PGF~2α~ according to FEN1 rs174537 G \> T in men at baseline (□) and 3-year follow-up (▪).\
**Notes:**^†^*P* \< 0.05; ^††^*P* \< 0.01 for baseline vs 3 years, tested by paired *t*-test; ^‡^*P* \< 0.05; ^‡‡^*P* \< 0.01; and ^‡‡‡^*P* \< 0.001 for GG vs T-allele group, tested by independent *t*-test; \*after adjusting for baseline values. Changes are differences between baseline and 3 years; values are means ± standard error.\
**Abbreviation:** 8-epi-PGF~2α~, urinary 8-epi-prostaglandin F~2α~.](cia-8-585f1){#f1-cia-8-585}

![Relation of changes in serum phospholipid arachidonic acid with changes in oxidized LDL, urinary 8-epi-PGF~2α~ and serum IL-6 in all male subjects.\
**Note:** Changes are differences between baseline and 3 years.\
**Abbreviations:** 8-epi-PGF~2α~, urinary 8-epi-prostaglandin F~2α~; LDL, low-density lipoprotein; IL, interleukin.](cia-8-585f2){#f2-cia-8-585}

###### 

Clinical characteristics, PUFA composition in serum phospholipids, and macronutrition intake at baseline and at 3 years

  **n = 122**                                                                    **Baseline**    **3-year follow-up**   ***P***
  ------------------------------------------------------------------------------ --------------- ---------------------- ---------
  Age (years)                                                                    46.7 ± 0.58     49.7 ± 0.60            \<0.001
  Body mass index (kg/m^2^)                                                      24.0 ± 0.20     24.1 ± 0.20            0.501
  Systolic blood pressure (mmHg)                                                 120.3 ± 1.10    119.6 ± 1.29           0.483
  Diastolic blood pressure (mmHg)                                                74.5 ± 0.88     74.8 ± 1.05            0.679
  Fasting glucose (mg/dL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}            92.1 ± 0.86     93.5 ± 0.85            0.121
  Triglyceride (mg/dL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}               131.3 ± 6.96    133.4 ± 7.61           0.901
  Total cholesterol (mg/dL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}          191.3 ± 3.10    193.3 ± 3.07           0.367
  LDL cholesterol (mg/dL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}            117.0 ± 3.17    121.7 ± 2.85           0.018
  HDL cholesterol (mg/dL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}            49.6 ± 1.15     46.4 ± 1.08            0.001
  hs-CRP (mg/dL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}                     1.64 ± 0.42     1.55 ± 0.29            0.601
  Serum TNF-α (pg/mL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}                11.4 ± 1.01     10.4 ± 0.88            0.856
  Serum IL-6 (pg/mL)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}                 4.58 ± 0.33     3.63 ± 0.26            0.004
  Oxidized LDL (U/L)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}                 34.8 ± 1.26     44.7 ± 1.15            \<0.001
  8-epi-PGF~2α~ (pg/mg creatinine)[^§^](#tfn13-cia-8-585){ref-type="table-fn"}   1318.6 ± 46.6   1363.7 ± 45.2          0.323
  **PUFA composition (%) in serum PL**                                                                                  
  Total polyunsaturated                                                          19.1 ± 0.38     19.1 ± 0.46            0.983
  ω6 FA                                                                                                                 
  18:2 (ω6)                                                                      12.0 ± 0.28     11.8 ± 0.32            0.621
  18:3 (ω6)                                                                      0.17 ± 0.01     0.20 ± 0.01            0.024
  20:2 (ω6)                                                                      0.67 ± 0.12     0.43 ± 0.08            0.016
  20:3 (ω6)                                                                      1.44 ± 0.04     1.43 ± 0.05            0.977
  20:4 (ω6)                                                                      4.36 ± 0.14     4.78 ± 0.19            0.043
  Total polyunsaturated                                                          4.66 ± 0.17     5.03 ± 0.20            0.123
  ω3 FA                                                                                                                 
  18:3 (ω3)                                                                      0.17 ± 0.02     0.19 ± 0.01            0.425
  20:3 (ω3)                                                                      0.09 ± 0.01     0.07 ± 0.00            0.054
  20:5 (ω3)                                                                      1.12 ± 0.05     1.26 ± 0.07            0.115
  22:5 (ω3)                                                                      0.57 ± 0.03     0.58 ± 0.03            0.727
  22:6 (ω3)                                                                      2.71 ± 0.12     2.93 ± 0.13            0.171
  **Estimates of daily nutrient intakes**                                                                               
  Total energy intake (kcal)                                                     2440.2 ± 19.1   2425.7 ± 15.8          0.399
  Carbohydrate (% of energy)                                                     61.5 ± 0.13     61.5 ± 0.08            0.672
  Protein (% of energy)                                                          16.8 ± 0.12     16.5 ± 0.07            0.114
  Fat (% of energy)                                                              21.6 ± 0.14     21.7 ± 0.11            0.794
  Total energy expenditure (kcal)                                                2361.5 ± 16.7   2333.0 ± 13.7          0.085

**Notes:**

Tested by logarithmic transformation, *P*-values derived from paired *t*-test. Values are means ± standard error.

**Abbreviations:** PUFA, polyunsaturated fatty acid; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; TNF, tumor necrosis factor; IL, interleukin; 8-epi-PGF~2α~, urinary 8-epi-prostaglandin F~2α~.

###### 

Associations of *FEN1* rs174537 genotypes with PUFA composition in serum phospholipids in men at baseline and 3-year follow-up

                                         ***FEN1* rs174537**                                            
  -------------------------------------- --------------------- ------- -------------- ------- --------- -------
  **PUFA composition (%) in serum PL**                                                                  
  18:2 (ω6)                                                                                             
    Baseline                             11.9 ± 0.42           0.957   12.1 ± 0.38    0.518   0.685     
    Follow-up                            11.9 ± 0.52                   11.8 ± 0.41            0.835     
    Change                               0.03 ± 0.52                   −0.34 ± 0.53           0.627     0.753
  18:3 (ω6)                                                                                             
    Baseline                             0.18 ± 0.02           0.303   0.16 ± 0.01    0.031   0.413     
    Follow-up                            0.20 ± 0.01                   0.20 ± 0.01            0.584     
    Change                               0.02 ± 0.02                   0.03 ± 0.01            0.659     0.652
  20:2 (ω6)                                                                                             
    Baseline                             0.61 ± 0.19           0.158   0.72 ± 0.16    0.030   0.665     
    Follow-up                            0.33 ± 0.03                   0.51 ± 0.14            0.287     
    Change                               −0.28 ± 0.19                  −0.21 ± 0.09           0.733     0.313
  20:3 (ω6)                                                                                             
    Baseline                             1.53 ± 0.07           0.926   1.37 ± 0.06    0.903   0.081     
    Follow-up                            1.53 ± 0.09                   1.36 ± 0.06            0.101     
    Change                               0.01 ± 0.10                   −0.01 ± 0.08           0.880     0.184
  20:4 (ω6)                                                                                             
    Baseline                             4.79 ± 0.23           0.022   4.04 ± 0.16    0.587   0.007     
    Follow-up                            5.61 ± 0.30                   4.17 ± 0.21            \<0.001   
    Change                               0.81 ± 0.34                   0.14 ± 0.25            0.108     0.001
  18:3 (ω3)                                                                                             
    Baseline                             0.17 ± 0.03           0.742   0.17 ± 0.03    0.463   0.998     
    Follow-up                            0.19 ± 0.01                   0.20 ± 0.02            0.589     
    Change                               0.01 ± 0.03                   0.02 ± 0.03            0.760     0.591
  20:3 (ω3)                                                                                             
    Baseline                             0.10 ± 0.02           0.037   0.08 ± 0.01    0.613   0.153     
    Follow-up                            0.07 ± 0.00                   0.07 ± 0.00            0.392     
    Change                               −0.04 ± 0.02                  −0.01 ± 0.01           0.108     0.408
  20:5 (ω3)                                                                                             
    Baseline                             1.19 ± 0.08           0.090   1.07 ± 0.06    0.787   0.231     
    Follow-up                            1.49 ± 0.14                   1.09 ± 0.07            0.010     
    Change                               0.30 ± 0.18                   0.02 ± 0.08            0.153     0.004
  22:5 (ω3)                                                                                             
    Baseline                             0.54 ± 0.04           0.044   0.59 ± 0.05    0.213   0.441     
    Follow-up                            0.66 ± 0.04                   0.53 ± 0.03            0.016     
    Change                               0.12 ± 0.06                   −0.06 ± 0.05           0.019     0.011
  22:6 (ω3)                                                                                             
    Baseline                             2.81 ± 0.20           0.134   2.64 ± 0.15    0.649   0.495     
    Follow-up                            3.20 ± 0.20                   2.73 ± 0.16            0.071     
    Change                               0.39 ± 0.26                   0.09 ± 0.20            0.354     0.088
  20:4 (ω6)/20:3 (ω6)                                                                                   
    Baseline                             3.26 ± 0.15           0.007   3.33 ± 0.35    0.808   0.882     
    Follow-up                            3.96 ± 0.25                   3.24 ± 0.19            0.019     
    Change                               0.70 ± 0.25                   −0.09 ± 0.36           0.101     0.017
  20:4 (ω6)/18:2 (ω6)                                                                                   
    Baseline                             0.43 ± 0.03           0.202   0.34 ± 0.01    0.237   0.007     
    Follow-up                            0.53 ± 0.06                   0.41 ± 0.05            0.146     
    Change                               0.10 ± 0.07                   0.06 ± 0.05            0.719     0.185
  20:5 (ω3)/18:3 (ω3)                                                                                   
    Baseline                             9.55 ± 0.88           0.328   9.06 ± 0.87    0.024   0.694     
    Follow-up                            8.42 ± 0.71                   6.69 ± 0.53            0.048     
    Change                               −1.13 ± 1.14                  −2.37 ± 1.02           0.426     0.048

**Notes:**

Values derived from paired *t*-test;

values derived from independent *t*-test;

values derived after adjusting for baseline values. Values are means ± standard error.

**Abbreviations:** PUFA, polyunsaturated fatty acid; PL, phospholipid.

###### 

Associations of *FEN1* rs174537 genotypes with LDL-cholesterol, hs-CRP, cytokines, and oxidative stress markers in men at baseline and 3-year follow-up

                                                            ***FEN1*rs174537**                                               
  --------------------------------------------------------- -------------------- --------- --------------- --------- ------- ---------
  LDL cholesterol (mg/dL)                                                                                                    
    Baseline[^§^](#tfn21-cia-8-585){ref-type="table-fn"}    117.8 ± 4.61         0.043     116.5 ± 4.31    0.145     0.830   
    Follow-up[^§^](#tfn21-cia-8-585){ref-type="table-fn"}   123.3 ± 3.92                   120.7 ± 3.99              0.498   
    Change                                                  5.50 ± 3.11                    4.21 ± 3.25               0.785   0.677
  hs-CRP (mg/dL)                                                                                                             
    Baseline[^§^](#tfn21-cia-8-585){ref-type="table-fn"}    1.38 ± 0.35          0.828     1.82 ± 0.67     0.424     0.751   
    Follow-up[^§^](#tfn21-cia-8-585){ref-type="table-fn"}   1.46 ± 0.35                    1.62 ± 0.43               0.603   
    Change                                                  0.08 ± 0.18                    −0.20 ± 0.79              0.769   0.623
  Serum IL-6 (pg/mL)                                                                                                         
    Baseline[^§^](#tfn21-cia-8-585){ref-type="table-fn"}    3.83 ± 0.42          0.557     5.07 ± 0.47     0.001     0.038   
    Follow-up[^§^](#tfn21-cia-8-585){ref-type="table-fn"}   3.90 ± 0.46                    3.44 ± 0.30               0.702   
    Change                                                  0.07 ± 0.49                    −1.63 ± 0.54              0.030   0.307
  Serum TNF-α (pg/mL)                                                                                                        
    Baseline[^§^](#tfn21-cia-8-585){ref-type="table-fn"}    11.7 ± 1.42          0.943     11.2 ± 1.40     0.863     0.467   
    Follow-up[^§^](#tfn21-cia-8-585){ref-type="table-fn"}   12.0 ± 2.02                    9.26 ± 0.55               0.376   
    Change                                                  0.33 ± 2.27                    −1.95 ± 1.40              0.369   0.089
  8-epi-PGF~2α~ (pg/mg creatinine)                                                                                           
    Baseline[^§^](#tfn21-cia-8-585){ref-type="table-fn"}    1342.7 ± 60.4        0.156     1301.0 ± 67.9   0.995     0.349   
    Follow-up[^§^](#tfn21-cia-8-585){ref-type="table-fn"}   1531.8 ± 86.7                  1240.1 ± 40.1             0.011   
    Change                                                  189.2 ± 104.5                  −60.9 ± 78.2              0.053   \<0.001
  Oxidized LDL (U/L)                                                                                                         
    Baseline[^§^](#tfn21-cia-8-585){ref-type="table-fn"}    33.1 ± 1.77          \<0.001   36.1 ± 1.76     \<0.001   0.292   
    Follow-up[^§^](#tfn21-cia-8-585){ref-type="table-fn"}   45.2 ± 1.53                    44.3 ± 1.64               0.373   
    Change                                                  12.2 ± 1.83                    8.19 ± 1.70               0.119   0.241

**Notes:**

Tested by logarithmic transformation;

values derived from paired *t*-test;

values derived from independent *t*-test;

values derived after adjusting for baseline value. Values are means ± standard error.

**Abbreviations:** PUFA, polyunsaturated fatty acid; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; TNF, tumor necrosis factor; IL, interleukin; 8-epi-PGF~2α~, urinary 8-epi-prostaglandin F~2α~.

###### 

Correlations between 8-epi-PGF~2α~ and cytokine

           **8-epi-PGF~2α~**   **IL-6**           
  -------- ------------------- ---------- ------- ---------
  IL-6     0.242               0.015      --      --
  TNF-α    0.246               0.013      0.464   \<0.001
  hs-CRP   0.085               0.364      0.507   \<0.001

**Abbreviations:** 8-epi-PGF~2α~, urinary 8-epi-prostaglandin F~2α~ ; IL, interleukin; TNF, tumor necrosis factor; hsCRP, high-sensitivity C-reactive protein C-reactive protein.

[^1]: These authors contributed equally to this work
